多西他赛和 S-1 联合治疗晚期或复发性胃癌患者的一线治疗：回顾性分析。
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis.
机构信息
Department of Surgery, Division of Frontier Medical Science, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan.
出版信息
World J Surg Oncol. 2010 May 19;8:40. doi: 10.1186/1477-7819-8-40.
BACKGROUND
We performed a single-institution retrospective study to evaluate the efficacy and toxicities of combination therapy with docetaxel and S-1 in patients with advanced or recurrent gastric cancer.
METHODS
Eighty-six patients with advanced or recurrent gastric cancer were enrolled. Patients received docetaxel, 40 mg/m2, on day 1 and oral S-1, 80 mg/m2/day, on days 1 to 14 every 3 weeks.
RESULTS
All 84 patients were assessable for response. The overall response rate was 52.4% (44/84) and the disease control rate was 96.4% (81/84). Median time to progression (TTP) and overall survival (OS) were 6.5 (95% CI, 4.8-8.1 months) and 15.1 months (95% CI, 11.7-18.5 months), respectively. The major toxicities were neutropenia, leukopenia, alopecia and anorexia. Grade 3 or 4 hematologic toxicities included neutropenia in 31 patients (36.0%), leukopenia in 27 (31.7%), febrile neutropenia in four (4.7%), and anemia in one (1.2%). Other grade 3 toxicities included anorexia in five patients (5.8%), and stomatitis, diarrhea and nausea in one each (1.2%). There was one treatment-related death (1.2%).
CONCLUSION
The combination of docetaxel and S-1 had good clinical activity with acceptable toxicity in patients with advanced or recurrent gastric cancer.
背景
我们进行了一项单机构回顾性研究，以评估多西紫杉醇和 S-1 联合治疗晚期或复发性胃癌患者的疗效和毒性。
方法
共纳入 86 例晚期或复发性胃癌患者。患者接受多西紫杉醇，40mg/m2，第 1 天；S-1，80mg/m2/天，第 1 天至第 14 天，每 3 周 1 次。
结果
84 例患者均可评估疗效。总缓解率为 52.4%（44/84），疾病控制率为 96.4%（81/84）。中位无进展生存期（TTP）和总生存期（OS）分别为 6.5（95%CI，4.8-8.1 个月）和 15.1 个月（95%CI，11.7-18.5 个月）。主要毒性为中性粒细胞减少、白细胞减少、脱发和厌食。3 级或 4 级血液学毒性包括 31 例（36.0%）中性粒细胞减少、27 例（31.7%）白细胞减少、4 例（4.7%）发热性中性粒细胞减少和 1 例（1.2%）贫血。其他 3 级毒性包括 5 例（5.8%）厌食、1 例（1.2%）口腔炎、1 例（1.2%）腹泻和 1 例（1.2%）恶心。有 1 例（1.2%）治疗相关死亡。
结论
多西紫杉醇和 S-1 联合治疗晚期或复发性胃癌患者具有良好的临床活性，毒性可接受。
Zotero 插件